Surrogate end point fallacies - The urge for randomized trials with clinical endpoints;Evidence based medicine: Widersprüche zwischen surrogatergebnissen und klinischen endpunkten

PPmP Psychotherapie Psychosomatik Medizinische Psychologie

Volumn 56, Issue 5, 2006, Pages 193-201

  Mühlhauser, Ingrid ^a   Meyer, Gabriele ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Biological markers; Evidence based medicine; Treatment outcome

Indexed keywords

ANTIDIABETIC AGENT; VITAMIN;

ARTICLE; CARDIOVASCULAR RISK; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; MORBIDITY; MORTALITY; NURSING; POLICY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; BIOASSAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; STANDARD; STATISTICS; TREATMENT OUTCOME;

ENDPOINT DETERMINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 33744999603     PISSN: 09372032     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-915449     Document Type: Article

References (71)

1. Meyer G, Mühlhauser I. Der Hormon-Trugschluss: Sexualhormone (Östrogene/Gestagene) in der Meno-/Postmenopause zur Krankheitsverhü tung und Lebensverlängerung. In: Schücking BA (Hrsg): Selbstbestimmung der Frau in Gynäkologie und Geburtshilfe. Osnabrück: V&R unipress, 2003: 103-119
2. Mühlhauser I, Meyer G. Hormontherapie in den Wechseljahren. Kritische Blicke auf die Evidenzbasis. In: Jahn I (Hrsg): Wechseljahre multidisziplinär. Was wollen Frauen - was brauchen Frauen. St. Augustin: Asgard-Verlag, 2004: 139-162
3. Sackett DL. Hormone replacement therapy. The arrogance of preventive medicine. CMAJ 2002; 167: 263-364
4. Petitti D. Commentary: Hormone replacement therapy and coronary heart disease: four lessons. Internat J Epidemiol 2004; 33: 461-463
5. Hulley S, Grady D, Bush T et al, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613
6. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333
7. Shumaker SA, Legault C, Thal L et al, for the WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651-2662
8. Shumaker SA, Legault C, Kuller L et al. Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291: 2947-2958
9. Espeland MA, Rapp SR, Shumaker SA et al. Women's Health Initiative Memory Study. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291: 2959-2968
10. Hendrix SL, Cochrane BB, Nygaard IE et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 2005; 293: 935-948
11. Hemminki E, Sihvo S. A review of postmenopausal hormone therapy recommendations: potential for selection bias. Obstet Gynecol 1993; 82: 1021-1028
12. Mühlhauser I, Kimmerle R, Berger M. Langzeittherapie mit Sexualhormonen zur Krankheitsverhütung und Lebensverlängerung in der Postmenopause. Offene Fragen und Kontroversen unter besonderer Berücksichtigung des Diabetes mellitus. arznei-telegramm 1995; 26: 37-44
13. Mühlhauser I. Kohortenstudie versus randomisiert-kontrollierte Studie am Beispiel der Behandlung mit Sexualhormonen in der Postmenopause. Diab Stoffw 1999; 8: 281-286
14. Mühlhauser I, Meyer G. Die so genannte Hormonersatztherapie in der Meno-/Postmenopause. Z Allg Med 2000; 76: 497-501
15. Kuhl H. Postmenopausale Frauen: Kardiovaskuläre Protektion durch Östrogen/Gestagen-Substitution. Dtsch Ärztebl 1996; 93: A1116-1119
16. Kuhl H. Substitution mit Östrogenen und Gestagenen. 11. Arbeitstreffen des "Zürcher Gesprächskreises". Dtsch Ärztebl 1994; 91: B571-573
17. Lauritzen C. Hormonsubstitution in der Menopause. Konsensus der Menopausegesellschaft deutschsprachiger Länder. Dtsch Ärztebl 1993; 90: B694-696
18. Mühlhauser I, Berger M. Surrogat-Marker. Trugschlüsse. Dtsch Ärztebl 1996; 93: A3280-3283
19. Bucher H, Guyatt GH, Cook D et al. Users' guides to the medical literature. XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. JAMA 1999; 282: 771-778
20. Berger M, Mühlhauser I. Wirksamkeit von Medikamenten muss auch nach Zulassung geprüft werden. Dtsch Ärztebl 2000; 97: A154-156
21. Hays J, Ockene JK, Brunner RL et al. for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348: 1839-1854
22. Chlebowski RT, Hendrix SL, Langer RD et al, for the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized Trial. JAMA 2003; 289: 3243-3253
23. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al, for the Women's Health Initiative Investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350: 991-1004
24. Cauley JA, Black DM, Barrett-Connor E et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med 2001; 110: 442-450
25. Steckelberg A, Berger B, Köpke S et al. Kriterien für evidenzbasierte Patienteninformationen. Z Ärztl Fortbild Qualitätssich 2005; 99: 343-351
26. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330; 1029-1035
27. Omenn GS, Goodman GE, Thornquist MD et al. Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-1155
28. Graat JM, Schouten EG, Kok FJ. Effect of daily vitamin E and multivitamin-mineral supplementation on acute respiratory tract infections in elderly persons. A randomized controlled trial. JAMA 2002; 288: 715-721
29. Miller ER, Pastor-Barriuso R, Dalal D et al. Meta-analysis: high dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46
30. The Cardiac Arrhythmia Supression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412
31. Epstein AE, Hallstrom AP, Rogers WJ et al. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the cardiac arrhythmia suppression trial (CAST). JAMA 1993; 270: 2451-2455
32. Moore TJ. Deadly Medicine. Why tens of thousands of heart patients died in America's worst drug disaster. New York, London, Toronto: Simon & Schuster, 1995
33. Waldo AL, Caunn AJ, Ruyter H de et al, for the SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348:7-12
34. Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-1475
35. Califf RM, Adams FK, McKenna WJ et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure. Am Heart J 1997; 134: 44-54
36. Hampton JR, Veldhuisen DJ van, Kleber FX et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997; 349: 971-977
37. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069-1118
38. Commitee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984; 2: 600-604
39. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study. Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245
40. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000; 102: 21-27
41. Strandberg TE, Salomaa VV, Naukkarinen VA et al. Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men. JAMA 1991; 266: 1225-1229
42. Strandberg TE, Salomaa VV, Naukkarinen VA et al. Cardiovascular morbidity and multifactorial primary prevention: fifteen-year follow-up of the Helsinki businessmen study. Nutr Metab Cardiovasc Dis 1995; 5: 7-15
43. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to Doxazosin vs Chlorthalidone. JAMA 2000; 283: 1967-1975
44. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes mellitus. II. Mortality results 1970; 10(Suppl 2): 785-830
45. University Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy. Diabetes 1975; 24 (Suppl 1): 65-184
46. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on non-fatal events treated with tolbutamide. Diabetes 1976; 25: 1129-1152
47. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
48. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
49. Mühlhauser I. UKPDS - Darstellung nach Evidence-based Medicine Kriterien. Diabetes & Stoffwechsel 1998; 7: 267-273
50. Berger M, Mühlhauser I. Diabetes care and patient-oriented outcomes. JAMA 1999; 281: 1676-1678
51. Riggs BL, Hodgson SF, O'Fallon WM et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802-809
52. Pak CY, Sakhaee K, Adams-Huet B et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 1995; 123: 401-408
53. Reginster JY, Meurmans L, Zegels B et al. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med 1998; 129: 1-8
54. Ringe JD, Dorst A, Kipshoven C et al. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate. Osteoporos Int 1998; 8: 47-52
55. Meunier PJ, Sebert JL, Reginster JY et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVO Study. Osteoporos Int 1998; 8: 4-12
56. Ringe JD, Kipshoven C, Coster A et al. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate. Osteoporos Int 1999; 9: 171-178
57. Odvina CV, Zerwekh JE, Rao DS et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294-1301
58. Anonym. Kiefernekrosen unter Bisphosphonaten - Ein Klasseneffekt? arznei-telegramm 2005; 36: 23-24
59. Anonym. Antidepressiva: Lebensgefährliche Plazebos? arznei-telegramm 2005; 36: 45-47
60. Emmerik AAP, Kamphuis JH, Hulsbosch AM et al. Single session debriefing after psychological trauma: a meta-analysis. Lancet 2002; 360: 766-771
61. Rose S, Bisson J, Wesseley S. A systematic review of single-session psychological interventions ("debriefing") following trauma. Psychother Psychosom 2003; 72: 176-184
62. Michael T, Lajtman M, Margaf J. Frühzeitige psychologische Interventionen nach Traumatisierung. Dtsch Ärztebl 2005; 102: A 2240-2243
63. Watson M, Kendrick D, Coupland C et al. Providing child safety equipment to prevent injuries: randomised controlled trial. BMJ 2005; 330: 178-181
64. Petrosino A, Turpin-Petrosino C, Buehler J. "Scared Straight" and other juvenile awareness programs for preventing juvenile delinquency. The Cochrane Database of Systematic Reviews 2002; Issue 2: CD002796
65. Schlömer G. RCTs und systematic reviews in der Pflegeliteratur: Ein Vergleich zwischen deutscher und internationaler Pflegeforschung. Pflege 1999; 12: 250-258
66. Fraser I, Askew A, Biles J et al. Prospective randomised trial of early postoperative bathing. BMJ 1976; 6024: 1506-1507
67. Neues C, Haas E. Beeinflussung der postoperativen Wundheilung durch Duschen. Chirurg 2000; 71: 234-236
68. Riederer SR, Inderbitzi R. Gefährdet das Duschen die postoperative Wundheilung? Chirurg 1997; 68: 715-717
69. Kjonniksen I, Andersen BM, Sondenaa VG et al. Preoperative hair removal. A systematic literature review. AORN Journal 2002; 75: 928-938, 940
70. Deutsches Netzwerk für Qualitätsentwicklung in der Pflege (Hrsg). Expertenstandard Sturzprophylaxe in der Pflege. Osnabrück: 2005
71. Kerse N, Butler M, Robinson E et al. Fall prevention in residential care: a cluster, randomized, controlled trial. J Am Geriatr Soc 2004; 52: 524-531